3 results
Approved WMORecruitment stopped
The objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response and blood counts and can be use as front-line therapy for SAA treatment.
Approved WMOWill not start
Core StudyPrimary objective• To compare the efficacy of E5501 (in addition to standard of care) to eltrombopag (in addition to standard of care) for the treatment of adult subjects with chronic immune thrombocytopenia (idiopathic thrombocytopenic…
Approved WMOWill not start
To compare the effect of eltrombopag and IVIG on the achievement of the platelet count threshold before and after surgery.